Institutional Fund
Avidity Partners Management LP
Dallas, TXCIK 17918276 filings on record
Portfolio Value
$493.81M
Q1 2026
Holdings
45
Reported positions
New Buys
21
Opened this quarter
QoQ Change
+42.4%
from $346.69M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Dianthus Therapeutics Inc35.8%
- Cg Oncology Inc17.7%
- Oruka Therapeutics Inc7.6%
- Perspective Therapeutics Inc5.1%
- Jade Biosciences Inc4.0%
- Enliven Therapeutics Inc3.2%
- Other26.8%
Portfolio Holdings
45 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Dianthus Therapeutics Inc | 2.10M | $176.58M | 35.8% | 0 | Held |
| 2 | Cg Oncology Inc | 1.29M | $87.24M | 17.7% | −183.8K | Reduced |
| 3 | Oruka Therapeutics Inc | 760.4K | $37.30M | 7.6% | +100.0K | Added |
| 4 | Perspective Therapeutics Inc | 6.05M | $25.23M | 5.1% | +2.84M | Added |
| 5 | Jade Biosciences Inc | 1.40M | $19.68M | 4.0% | 0 | Held |
| 6 | Enliven Therapeutics Inc | 400.0K | $15.68M | 3.2% | +259.7K | Added |
| 7 | Teva Pharmaceutical Inds Ltd | 450.1K | $13.56M | 2.7% | +32.8K | Added |
| 8 | Context Therapeutics Inc | 5.00M | $13.10M | 2.7% | −506.6K | Reduced |
| 9 | Repligen Corp | 77.8K | $9.17M | 1.9% | +27.5K | Added |
| 10 | Palvella Therapeutics Inc Ne | 70.0K | $8.73M | 1.8% | +50.7K | Added |
35 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio